Biomedical imaging has a crucial role in (pre)clinical research, drug development, medical diagnosis and assessment of therapy response. Often, the images are tomographic: from the measured data, (stacks of) slices or volumes representing anatomical and functional properties of the patient can be reconstructed using sophisticated algorithms. Increasingly, images from multiple types of systems such as Magnetic Resonance (MR), radionuclide imaging using Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) and X-ray Computed Tomography (CT) are analysed together. Image quality is critically dependent on image reconstruction methods. Development and testing of novel algorithms on patient data require considerable expertise and effort in software implementation. In our previous CCP on synergistic reconstruction for PET-MR, we created a network of UK and international researchers working towards integrating image reconstruction of data from integrated, simultaneous, PET-MR scanners. New multi-modality systems are now available or under development, for instance SPECT-MR or even tri-modality PET-SPECT-CT systems. At the same time, top-of-the-range multi-modality systems are expensive and instead combining single-modality scans from different time-points and systems can provide more cost-effective solutions in some cases. Synergistic image reconstruction aims to exploit the commonalities between the data from the different modalities and time points. However, cross-modality methods are particularly challenging. We will therefore extend the network to exploit synergy in multi-modal, multi-contrast, multi-time point information for biomedical applications, concentrating on the logistical and computational aspects of synergistic image reconstruction. The Open Source Software platform to be provided by this CCP will be an enabling technology which removes the frequent obstacles encountered when working with the raw medical imaging datasets, accelerating innovative developments in image reconstruction, and ultimately enabling the possibility of synergistic image reconstruction by establishing validated pipelines for processing raw data of multiple data-sets.

Numerous chronic diseases, such as cancer and early heart disease, are often symptomless. Consequently, these diseases are often diagnosed at a late stage which reduces the treatment options that are available to the patient. We are creating new ways of seeing inside the body to identify the processes that go wrong with these devastating diseases using a process called 'molecular imaging'. These innovative scans require the administration of radioactive drugs into the blood stream. The drugs home to the site of the disease, or identify a particular feature related to the disease that will help medical professionals provide the correct treatments for the specific patient. The radioactivity is needed so advanced medical scanners can identify the disease location in the body. Instead of taking a picture of the outside, these scanners can see deep within the body and locate regions of disease that are just millimetres in size. The type and amount of radioactivity used are not harmful but provide the 'beacon' so these diseases can visualised by the scanner. At King's College London we have pioneered the discovery of new molecular imaging applications for the past fifteen+ years. We have built a critical mass and extensive research infrastructure to make pioneering discoveries in molecular imaging research with the ultimate goal of improving human health. This exciting area of research is now on the cusp of new discoveries to not only see but treat disease. By changing the nature of the radioactivity attached to the drug we can deliver a targeted therapeutic payload to the site of disease, resulting in its elimination. Known as 'radionuclides therapies', they have already shown improvements over normal chemotherapy in prostate cancer patients with a lower number of side effects. At King's College London we have the facilities, know-how and ambition to make a significant contribution to this emerging field of research. To fully exploit our critical mass in molecular imaging and radionuclide research we require new scanners to detect both imaging and therapeutic radioactivity. Here, we have requested funds to purchase miniaturised clinical scanners for research using animal models of human diseases. Replacing our >12-year-old equipment they possess advanced features that enable researchers to develop and optimise these imaging tools before their use in humans. Specifically, we will be able to track the movement of these radioactivity-based treatments throughout the body in real time. The improved resolution of the scans will also allow us to identify microstructures in the body or track just a few thousand therapeutic cells that are injected to fight cancer. Working with researchers across the UK will use these scanners to improve our understanding of a host of different diseases including cancer, neurodegenerative disorders, heart disease, pregnancy, inflammatory disorders, and arthritis. Finally, by partnering with pharmaceutical and biotech companies we aim to commercialise these discoveries to deliver maximum benefit to a wide range of patients both in the UK and world-wide.

Medical imaging has transformed clinical medicine in the last 40 years. Diagnostic imaging provides the means to probe the structure and function of the human body without having to cut open the body to see disease or injury. Imaging is sensitive to changes associated with the early stages of cancer allowing detection of disease at a sufficient early stage to have a major impact on long-term survival. Combining imaging with therapy delivery and surgery enables 3D imaging to be used for guidance, i.e. minimising harm to surrounding tissue and increasing the likelihood of a successful outcome. The UK has consistently been at the forefront of many of these developments. Despite these advances we still do not know the most basic mechanisms and aetiology of many of the most disabling and dangerous diseases. Cancer survival remains stubbornly low for many of the most common cancers such as lung, head and neck, liver, pancreas. Some of the most distressing neurological disorders such as the dementias, multiple sclerosis, epilepsy and some of the more common brain cancers, still have woefully poor long term cure rates. Imaging is the primary means of diagnosis and for studying disease progression and response to treatment. To fully achieve its potential imaging needs to be coupled with computational modelling of biological function and its relationship to tissue structure at multiple scales. The advent of powerful computing has opened up exciting opportunities to better understand disease initiation and progression and to guide and assess the effectiveness of therapies. Meanwhile novel imaging methods, such as photoacoustics, and combinations of technologies such as simultaneous PET and MRI, have created entirely new ways of looking at healthy function and disturbances to normal function associated with early and late disease progression. It is becoming increasingly clear that a multi-parameter, multi-scale and multi-sensor approach combining advanced sensor design with advanced computational methods in image formation and biological systems modelling is the way forward. The EPSRC Centre for Doctoral Training in Medical Imaging will provide comprehensive and integrative doctoral training in imaging sciences and methods. The programme has a strong focus on new image acquisition technologies, novel data analysis methods and integration with computational modelling. This will be a 4-year PhD programme designed to prepare students for successful careers in academia, industry and the healthcare sector. It comprises an MRes year in which the student will gain core competencies in this rapidly developing field, plus the skills to innovate both with imaging devices and with computational methods. During the PhD (years 2 to 4) the student will undertake an in-depth study of an aspect of medical imaging and its application to healthcare and will seek innovative solutions to challenging problems. Most projects will be strongly multi-disciplinary with a principle supervisor being a computer scientist, physicist, mathematician or engineer, a second supervisor from a clinical or life science background, and an industrial supervisor when required. Each project will lie in the EPSRC's remit. The Centre will comprise 72 students at its peak after 4 years and will be obtaining dedicated space and facilities. The participating departments are strongly supportive of this initiative and will encourage new academic appointees to actively participate in its delivery. The Centre will fill a significant skills gap that has been identified and our graduates will have a major impact in academic research in his area, industrial developments including attracting inward investment and driving forward start-ups, and in advocacy of this important and expanding area of medical engineering.

We propose to create the EPSRC Centre for Doctoral Training (CDT) in intelligent integrated imaging in healthcare (i4health) at University College London (UCL). Our aim is to nurture the UK's future leaders in next-generation medical imaging research, development and enterprise, equipping them to produce future disruptive healthcare innovations either focused on or including imaging. Building on the success of our current CDT in Medical Imaging, the new CDT will focus on an exciting new vision: to unlock the full potential of medical imaging by harnessing new associated transformative technologies enabling us to consider medical imaging as a component within integrated healthcare systems. We retain a focus on medical imaging technology - from basic imaging technologies (devices and hardware, imaging physics, acquisition and reconstruction), through image computing (image analysis and computational modeling), to integrated image-based systems (diagnostic and interventional systems) - topics we have developed world-leading capability and expertise on over the last decade. Beyond this, the new initiative in i4health is to capitalise on UCL's unique combination of strengths in four complementary areas: 1) machine learning and AI; 2) data science and health informatics; 3) robotics and sensing; 4) human-computer interaction (HCI). Furthermore, we frame this research training and development in a range of clinical areas including areas in which UCL is internationally leading, as well as areas where we have up-and-coming capability that the i4health CDT can help bring to fruition: cancer imaging, cardiovascular imaging, imaging infection and inflammation, neuroimaging, ophthalmology imaging, pediatric and perinatal imaging. This unique combination of engineering and clinical skills and context will provide trainees with the essential capabilities for realizing future image-based technologies. That will rely on joint modelling of imaging and non-imaging data to integrate diverse sources of information, understanding of hardware the produces or uses images, consideration of user interaction with image-based information, and a deep understanding of clinical and biomedical aims and requirements, as well as an ability to consider research and development from the perspective of responsible innovation. Building on our proven track record, we will attract the very best aspiring young minds, equipping them with essential training in imaging and computational sciences as well as clinical context and entrepreneurship. We will provide a world-class research environment and mentorship producing a critical mass of future scientists and engineers poised to develop and translate cutting-edge engineering solutions to the most pressing healthcare challenges.